Andrea Corona Altimmunes GLP-1 drug shows positive results for alcohol use disorder On Tuesday, Altimmune announced topline data from their Phase 2 RECLAIM trial showing that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced the number of heavy drinking days compared to placebo in patients with moderate to severe alcohol use disorder
Oxidative stress and antioxidant markers (vitamins and antioxidant enzymatic activity) were determined in plasma every month
Embarking upon a voyage through the medicinal realms of Ozempic and Saxenda, we encounter a fascinating tableau where two drugs, originating from the same pharmaceutical tapestry, delineate distinct narratives within the healthcare odyssey
For compounded semaglutide products, which are not FDA-approved, patients should follow the specific storage instructions provided by their compounding pharmacy and contact them directly with any storage concerns
Bariatric surgery or weight loss medications like Contrave and Ozempic
Why do people switch from Wegovy to Mounjaro